Of interest, one of the two NPM1-mutated AML patients developed NPM1-mutated-specific CTL response after administration of preemptive DLI and achieved molecular CR, whereas in the remaining clinically non–responder case, NPM1-mutated-specific CTLs were already detectable before DLI and persisted, but without showing an increase, after DLI [59]. Here, NPM1 is linked to acute myeloid leukemia.